Pleiotropic effects of statin therapy: molecular mechanisms and clinical results

Chao Yung Wang, Ping Yen Liu, James K. Liao

研究成果: Review article同行評審

472 引文 斯高帕斯(Scopus)


Statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is required for cholesterol biosynthesis, and are beneficial in the primary and secondary prevention of cardiovascular disease. Most of the benefits of statin therapy are owing to the lowering of serum cholesterol levels. However, by inhibiting HMG-CoA reductase, statins can also inhibit the synthesis of isoprenoids, which are important lipid attachments for intracellular signaling molecules, such as Rho, Rac and Cdc42. Therefore, it is possible that statins might exert cholesterol-independent or 'pleiotropic' effects through direct inhibition of these small GTP-binding proteins. Recent studies have shown that statins might have important roles in diseases that are not mediated by cholesterol. Here, we review data from recent clinical trials that support the concept of statin pleiotropy and provide a rationale for their clinical importance.

頁(從 - 到)37-44
期刊Trends in Molecular Medicine
出版狀態Published - 2008 1月

All Science Journal Classification (ASJC) codes

  • 分子醫學
  • 分子生物學


深入研究「Pleiotropic effects of statin therapy: molecular mechanisms and clinical results」主題。共同形成了獨特的指紋。